Literature DB >> 12543673

Sterilizing activities of fluoroquinolones against rifampin-tolerant populations of Mycobacterium tuberculosis.

Yanmin Hu1, Anthony R M Coates, Denis A Mitchison.   

Abstract

The bactericidal activities of ciprofloxacin, ofloxacin, levofloxacin, moxifloxacin, and gatifloxacin were tested in three models of rifampin-tolerant Mycobacterium tuberculosis persisters. Model 1 was a 100-day-old, unshaken, anaerobically adapted culture in which serial dilutions of the quinolones were incubated for 5 days and CFU counts were then done In models 2 and 3, 100 mg of rifampin/liter was added to the 100-day culture for 5 or 7 days to produce tolerant organisms that did not grow on plates; the rifampin was then washed off, fresh medium was added to allow recovery of growth on plates, and the culture was incubated for 7 days before CFU counts. In model 2, the quinolones were added after rifampin had been washed off, whereas in model 3 the quinolones were added to the cultures containing rifampin. In models 1 and 2, ciprofloxacin had the least bactericidal activity, ofloxacin and levofloxacin had greater activities, and moxifloxacin and gatifloxacin had the greatest activities. In model 3, ofloxacin had no detectable activity whereas moxifloxacin killed about log(10) 0.279 CFU of the persisters per ml at concentrations attainable in lesions; isoniazid had virtually no activity. These findings predict that ofloxacin will not be found to have effective sterilizing activity in clinical studies now planned whereas moxifloxacin will be able to shorten treatment.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12543673      PMCID: PMC151758          DOI: 10.1128/AAC.47.2.653-657.2003

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  15 in total

1.  The need for new drugs against tuberculosis. Obstacles, opportunities, and next steps.

Authors:  R J O'Brien; P P Nunn
Journal:  Am J Respir Crit Care Med       Date:  2001-04       Impact factor: 21.405

Review 2.  The future challenges facing the development of new antimicrobial drugs.

Authors:  Anthony Coates; Yanmin Hu; Richard Bax; Clive Page
Journal:  Nat Rev Drug Discov       Date:  2002-11       Impact factor: 84.694

3.  A multicentre study of the early bactericidal activity of anti-tuberculosis drugs.

Authors:  F A Sirgel; P R Donald; J Odhiambo; W Githui; K C Umapathy; C N Paramasivan; C M Tam; K M Kam; C W Lam; K M Sole; D A Mitchison
Journal:  J Antimicrob Chemother       Date:  2000-06       Impact factor: 5.790

4.  The early bactericidal activity of drugs in patients with pulmonary tuberculosis.

Authors:  A Jindani; V R Aber; E A Edwards; D A Mitchison
Journal:  Am Rev Respir Dis       Date:  1980-06

5.  Detection of mRNA transcripts and active transcription in persistent Mycobacterium tuberculosis induced by exposure to rifampin or pyrazinamide.

Authors:  Y Hu; J A Mangan; J Dhillon; K M Sole; D A Mitchison; P D Butcher; A R Coates
Journal:  J Bacteriol       Date:  2000-11       Impact factor: 3.490

6.  Increased levels of sigJ mRNA in late stationary phase cultures of Mycobacterium tuberculosis detected by DNA array hybridisation.

Authors:  Y Hu; A R Coates
Journal:  FEMS Microbiol Lett       Date:  2001-08-07       Impact factor: 2.742

Review 7.  Tuberculosis. Scientific blueprint for tuberculosis drug development.

Authors: 
Journal:  Tuberculosis (Edinb)       Date:  2001       Impact factor: 3.131

8.  Effectiveness of once-weekly rifapentine and moxifloxacin regimens against Mycobacterium tuberculosis in mice.

Authors:  N Lounis; A Bentoucha; C Truffot-Pernot; B Ji; R J O'Brien; A Vernon; G Roscigno; J Grosset
Journal:  Antimicrob Agents Chemother       Date:  2001-12       Impact factor: 5.191

9.  In vitro and in vivo activities of gatifloxacin against Mycobacterium tuberculosis.

Authors:  Enrique J Alvirez-Freites; Janna L Carter; Michael H Cynamon
Journal:  Antimicrob Agents Chemother       Date:  2002-04       Impact factor: 5.191

10.  In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis.

Authors:  B Ji; N Lounis; C Maslo; C Truffot-Pernot; P Bonnafous; J Grosset
Journal:  Antimicrob Agents Chemother       Date:  1998-08       Impact factor: 5.191

View more
  55 in total

1.  Rifampicin sparing treatment protocols in posttransplant tuberculosis.

Authors:  Vivekanand Jha; Vinay Sakhuja
Journal:  Int Urol Nephrol       Date:  2004       Impact factor: 2.370

Review 2.  Pharmacokinetic and pharmacodynamic issues in the treatment of mycobacterial infections.

Authors:  E Nuermberger; J Grosset
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-03-13       Impact factor: 3.267

Review 3.  New antituberculous drugs in development.

Authors:  Umesh G Lalloo; Anish Ambaram
Journal:  Curr HIV/AIDS Rep       Date:  2010-08       Impact factor: 5.071

4.  Examining the basis of isoniazid tolerance in nonreplicating Mycobacterium tuberculosis using transcriptional profiling.

Authors:  Griselda Tudó; Ken Laing; Denis A Mitchison; Philip D Butcher; Simon J Waddell
Journal:  Future Med Chem       Date:  2010-08       Impact factor: 3.808

5.  Rifapentine, moxifloxacin, or DNA vaccine improves treatment of latent tuberculosis in a mouse model.

Authors:  Eric Nuermberger; Sandeep Tyagi; Kathy N Williams; Ian Rosenthal; William R Bishai; Jacques H Grosset
Journal:  Am J Respir Crit Care Med       Date:  2005-09-08       Impact factor: 21.405

6.  Activity of the fluoroquinolone DC-159a in the initial and continuation phases of treatment of murine tuberculosis.

Authors:  Zahoor Ahmad; Austin Minkowski; Charles A Peloquin; Kathy N Williams; Khisimuzi E Mdluli; Jacques H Grosset; Eric L Nuermberger
Journal:  Antimicrob Agents Chemother       Date:  2011-01-31       Impact factor: 5.191

7.  Novel gyrase mutations in quinolone-resistant and -hypersusceptible clinical isolates of Mycobacterium tuberculosis: functional analysis of mutant enzymes.

Authors:  Alexandra Aubry; Nicolas Veziris; Emmanuelle Cambau; Chantal Truffot-Pernot; Vincent Jarlier; L Mark Fisher
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

8.  Evaluation of MGIT 960-based antimicrobial testing and determination of critical concentrations of first- and second-line antimicrobial drugs with drug-resistant clinical strains of Mycobacterium tuberculosis.

Authors:  Annika Krüüner; Malcolm D Yates; Francis A Drobniewski
Journal:  J Clin Microbiol       Date:  2006-03       Impact factor: 5.948

Review 9.  Novel approaches to developing new antibiotics for bacterial infections.

Authors:  A R M Coates; Y Hu
Journal:  Br J Pharmacol       Date:  2007-08-20       Impact factor: 8.739

10.  Polyphosphate deficiency in Mycobacterium tuberculosis is associated with enhanced drug susceptibility and impaired growth in guinea pigs.

Authors:  Ramandeep Singh; Mamta Singh; Garima Arora; Santosh Kumar; Prabhakar Tiwari; Saqib Kidwai
Journal:  J Bacteriol       Date:  2013-04-12       Impact factor: 3.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.